Edwards Lifesciences (EW) Other Non-Current Liabilities (2009 - 2026)

Edwards Lifesciences' Other Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $555.4 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 55.31% year-over-year to $555.4 million; the TTM figure through Mar 2026 stood at $555.4 million (up 55.31% YoY), while the FY2025 annual figure was $502.7 million, up 34.66% from the prior year.
• Other Non-Current Liabilities was $555.4 million for Q1 2026 at Edwards Lifesciences, up from $502.7 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $555.4 million in Q1 2026 to a low of $59.1 million in Q1 2022.
• Historically, Other Non-Current Liabilities has averaged $323.8 million across 5 years, with a median of $316.1 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities sank 73.64% in 2022, then jumped 340.1% in 2023.
• A 5-year view of Other Non-Current Liabilities shows it stood at $267.5 million in 2022, then fell by 10.17% to $240.3 million in 2023, then soared by 55.35% to $373.3 million in 2024, then surged by 34.66% to $502.7 million in 2025, then grew by 10.48% to $555.4 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $555.4 million (Q1 2026), $502.7 million (Q4 2025), and $442.9 million (Q3 2025), per Business Quant data.